Clinical trial

Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer

NCT05472467

Study summary

ClinicalTrials.gov

Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Camrelizumab Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention stereotactic body radiation therapy Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Chemotherapy Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2021-12-21

PhasePHASE2

Conditions

Non-small Cell Lung Cancer Metastaticunresolved

Interventions

CamrelizumabDRUG

stereotactic body radiation therapyRADIATION

ChemotherapyDRUG

Sponsors & collaborators

Sichuan Cancer Hospital and Research Institutelead sponsor

Mapped research locations

ChengduSichuan, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05472467 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.